Advisory Board

The TTS Global Initiative thanks the following Advisory Board members for their advice and support:

Mark Rohrbaugh, Director, Office of Tech Transfer, National Institutes of Health, USA  (*NIH Liaison to Board)

Mark Rohrbaugh

Mark L. Rohrbaugh, Ph.D., J.D., serves as the Director, Office of Technology Transfer (OTT), National Institutes of Health (NIH), Department of Health and Human Services (HHS). OTT manages the patenting and commercial licensing of NIH and FDA intramural inventions and serves as te lead office within the HHS for the development of technology transfer policy.  the OTT portfolio is the largest biomedical patent and lincese portfolio among public sector institutions. Companies marketing hundreds of products under OTT licenses report annual sales approaching $6B. 26 FDA approved products have been brought to market, and 70 products are in private sector clinical trials. Mark serves on the National Science and Technology Council Technology Committee and the HHS Innovation Council and is Vice-Chair of the Public Health Service Technology Transfer Policy Board.  He advises the NIH and HHS on a wide range of intellectual property issues. He has represented the HHS at the Organization for Economic Cooperation and Development (OECD) and the World Health Organization (WTO).  Mark previously served as the Director of the Office of Technology Devepment, National Institute of Allergy and Infectious Diseases (NIAID). Prior to joining the NIH he conducted molecular and cell biology research at the University of Minnesota and two start-up companies. He received his Ph.D. in biochemistry from the Pennsylvania State University and a degree in law from the George Washington University Law School.

Anne Lane, Director, Biopharm, UCL, UK

Anne LaneAnne has a PhD in medicine from UCL and an Executive MBA from Molson Business School, Montreal. After research at UCL and Harvard Medical School, Anne worked for RTP Pharma Inc in Montreal, out-licensing and preparing valuations of the company’s portfolio for public listing. Anne joined UCL Ventures in 2000 and acted as consultant for the National Transfer Centre in the US. She is now Executive Director of UCLB, acts as Director and interim CEO on several of UCLB’s spinout companies and oversees the company’s licensing activity. Anne is also a member of the Licensing Executives Society (LES) and is on the committee for the Intellectual Property Lawyers Organisation (TIPLO).

Brian Kelly, Director, Technology Commercialization & Liaison, Cornell University, NYC, USA

Brian KellyBrian is Director of the CCTEC office in NYC serving the Weill Cornell Medical College.  He manages a portfolio of inventions focusing on oncology, metabolic diseases and endocrine disorders.

Prior to joining CCTEC, Brian served as Director of Intellectual Property for New York University's tech transfer office.  He has also held positions at the University of Minnesota as a Licensing Associate; Heide, Hyde & O'Donnell as a European Patent Attorney; and Smith, Kline & French as a Research Chemist.

Cécile Tharaud, CEO, Inserm Transfert, France

Dr. Tharaud joined Inserm in 2005 with a mission to reorganise technology transfer activities. In 2006 she was appointed CEO of Inserm Transfert, Inserm's private affiliate dedicated to all knowledge transfer activities. Dr. Tharaud previously had a ten-year career in the pharmaceutical and biotechnology industries. In 1993 she joined the French affiliate of Glaxo (now GlaxoSmithKline) as a Manager of New Product Strategy, before moving to the French affiliate of SmithKline Beecham in 1995 as Manager of Business Development. At SmithKline Beecham, Dr. Tharaud developed the business development function in France and actively evaluated product and technology licensing opportunities. In 1996, Dr. Tharaud joined Genset, a listed genomics company, as Director of Patents and Licensing. She was responsible for designing and executing the Company's intellectual property strategy. In 1999, Dr. Tharaud became Vice President, Operations. In 2001, Dr. Tharaud joined the transatlantic functional genomics company Valigen as Chief Operating Officer. At Valigen, Dr. Tharaud managed the integration of the 3-way merger that created this 170-employee company. From 2002 to 2004, Dr Tharaud run interim management positions for biotech companies, as well as consulting missions for venture capital firms with Biosciences Managers Ltd. Dr. Tharaud received an MBA from INSEAD, a PhD in molecular genetics and immunology from the Institut National Agronomique, and an MSc from the Ecole Polytechnique. Dr. Tharaud has also completed an advanced education course at the Centre of the Advanced Study and Research on Intellectual Property at the law school of the University of Washington, Seattle, USA.

Christian Stein,CEO,  Ascenion GmbH, Germany

Before becoming Chief Executive Officer of Ascenion in August 2001, Christian Stein headed the Patent and Licensing Agency of the German Human Genome Project (PLA) at the Fraunhofer Patent Centre for German Research for several years. In 2000 he also assumed responsibility for Bayern Patent, the patent initiative for Bavarian universities. He is founder and former Managing Director of Ventratec GmbH, which supports entrepreneurs in establishing technology-based companies. Christian holds a PhD in molecular biology and obtained a Master of Science (MSc) in the Management of Intellectual Property Law in London. During this period he was also Assistant Editor-in-Chief for the international journal Antiviral Chemistry & Chemotherapy and was instrumental in founding Retroscreen Ltd, a thriving spin-off of the London Hospital Medical College. He is consultant and advisor for several EU programmes and regional and national expert groups, and serves on the boards of a number of biotechnology companies. In June 2011 Christian Stein was elected Vice President of the Association of European Science & Technology Transfer Professionals, ASTP. In addition, he serves on the Board of Directors at ATTP (Alliance of Technology Transfer Professionals), the international body for professionals engaged in technology transfer.

Erik Lium, Assistant Vice Chancellor, Office of Technology, Innovation & Industry Partnerships, UCSF, USA

Erik LiumErik Lium, PhD, serves as the Assistant Vice Chancellor of the Office of Innovation, Technology & Alliances at the University of California, San Francisco (UCSF). Prior to this position he served as Assistant Vice Chancellor for Research, Director of the Industry Contracts Division and Interim Director of the Contracts & Grants Division of the Office of Sponsored Research, and Director of Business Development for the UCSF Diabetes Center & Immune Tolerance Network. Erik has advanced the research, instruction, and public service mission of UCSF through substantial improvements to institutional research support services, and contributed to UCSF being recognized as an institution committed to innovative research alliances. Erik was President of LabVelocity Inc., an information services company focused on accelerating life science R&D processes, prior to its acquisition in 2004. He served as a postdoctoral research scientist in the laboratory of J. Michael Bishop, MD at UCSF, and earned his PhD with honors from the Integrated Program in Cellular, Molecular, and Biophysical Studies at Columbia University in the laboratory of Saul J. Silverstein, Ph.D.

Gail Maderis, President & CEO, BayBIO, USA

Gail MaderisGail Maderis is President & CEO of BayBio, the industry organization representing and supporting Northern California’s life science community. As a former biotech CEO, Ms. Maderis brings deep experience and commitment to supporting the industry through enterprise development, peer-to-peer experience sharing, advocacy and support of education and workforce development. From 2003 to 2009, Ms. Maderis served as President and CEO of Five Prime Therapeutics, Inc., a privately held protein discovery and development company. At FivePrime, she successfully funded the company’s rapid growth through substantial private equity financings and corporate partnerships and took the company’s first novel cancer therapeutic from discovery into clinical trials. Prior to FivePrime, Ms. Maderis held senior executive positions at Genzyme Corporation, including founder and president of Genzyme Molecular Oncology. Ms. Maderis practiced management and strategy consulting with Bain & Co. She serves on the boards of NovaBay Pharmaceuticals, Opexa Therapeutics, BayBio, the Mayor’s Biotech Advisory Council of San Francisco and the HBS Healthcare Initiative. She received a BS in business from the UC Berkeley and an MBA from Harvard Business School.

Gary Howes, Partner, Fasken Martineau LLP, UK

Gary HoweGary Howes is the Managing Partner at Fasken Martineau LLP and is a member of Technology and Intellectual Property and Life Sciences practice groups.  Gary works almost exclusively in the pharmaceutical and biotech sectors advising on IP, commercial and regulatory matters, patent licensing and product acquisitions and disposals. His clients include both private and public companies. Clients benefit from Gary's acute industry specialisation, which enables him to provide legal advice within the context of the relevant commercial and regulatory background. Advice "in a vacuum" is never provided. Gary is named by European Counsel Life Science's Industry Report in its 'Super League for Intellectual Property'. Global Counsel has also 'highly recommended' him for his work in patent expertise, commercial IP and protection issues. He is regularly recommended in the Legal 500 and in Chambers UK, where he is referred to as a "marvel in commercial agreements". That publication also said "clients endorsed his incisive intellectual ability to reduce problems" and his "ability to communicate well with laymen in non-legal terms."

In 2007 Gary was short listed for "Deal Lawyer of the Year" award at the British Legal Awards which are sponsored by Legal Week.

Glenn Cross, COO, AusBiotech, Australia

Glenn CrossGlenn is the Chief Operating Officer of AusBiotech and is responsible for business development, finance and general operations. With 30 years' experience in general management, Glenn’s primary expertise lies in sales, marketing, finance, distribution and manufacturing in the life sciences market. Glenn has experience in finance, human resources and product development with extensive experience in product development and distribution networks both locally and internationally. He has extensive experience in key/large corporate account management and business development in Australia, Asia, Japan, Europe and North America.

Jacques Grassi, Director, Aviesan Institute for Health Technologies, France

Jacques GrassiSince 1980, Jacques Grassi worked at the French Atomic Energy Commission (CEA) in the Department of Pharmacology and Immunology, which he has headed up since 1997. He has devoted most of his research to developing immunoanalysis methods (over 200 publications). Research Director at the CEA. Co-developer of the test for the post-mortem diagnosis of BSE and scrapie, developed by the CEA and now marketed by Bio-Rad. Since July 2006, he has been Director of the CEA’s cross-disciplinary program "Health Technologies". PhD in sciences from Paris VI University

Jean Deregnaucourt, Director, Research Applications & Industrial Relations, Institut Pasteur, France

Jean DeregnaucourtJean Deregnaucourt was previously Director General of the most important French pole of competitiveness in the field of Health, the Medicen Paris Region, and prior to that Director of Biotechnology at the Ministry for Research, as well as co-founder of the biotech company Cellvir.  He was previously Vice President of “Total Project Management” and then Vice President of “Chemical and Pharmaceutical Development International” at Rhône-Poulenc Rorer (Sanofi-Aventis), and  president of the Pierre Fabre Research Institute.

Kevin Cullen, CEO, NewSouth Innovations Pty Limited, University of New South Wales, Australia

Kevin CullenKevin was appointed Director of Research and Enterprise (R&E) at the University of Glasgow in October 2003, and he is responsible for directing activities in order to achieve the research and enterprise objectives of the University. This includes working with the Vice-Principal of Research & Enterprise in developing the University’s research strategy and the development and implementation of the Knowledge Transfer / commercialisation strategy for the University. Kevin also leads the University’s involvement in many areas of Economic Development, particularly with Scottish Enterprise and through the European Structural Funds.

Kevin Noonan, Senior Partner, MBHB, USA

Kevin NoonanKevin E. Noonan is a partner with McDonnell Boehnen Hulbert & Berghoff LLP. An experienced biotechnology patent lawyer, Dr. Noonan brings more than 10 years of extensive work as a molecular biologist studying high-technology problems in serving the unique needs of his clients. His practice involves all aspects of patent prosecution, interferences, and litigation. He represents pharmaceutical companies both large and small on a myriad of issues, as well as several universities in both patenting and licensing to outside investors. He has also filed amicus briefs to district courts, the Federal Circuit and the Supreme Court involving patenting issues relevant to biotechnology.

Dr. Noonan is a frequent speaker, commentator and author on a variety of intellectual property law topics. He is a founding author of the Patent Docs weblog, a site focusing on biotechnology and pharmaceutical patent law. In 2010, he was interviewed for a segment that aired on the television program "60 Minutes" that addressed the issue of gene patenting.

Markus Goebel, Managing Director, Novartis Venture Fund, Switzerland

Markus GoebelMarkus Goebel previously he worked as head Pharma Corporate M&A and head Nervous System BD&L Pharma. An MD by training and certified, amongst others, in hematology/oncology he worked for Farmitalia Germany and later held several positions in R&D, Marketing and Strategy at Roche headquarters before joining Novartis. Markus Goebel received an MD and a PhD from the Ludwig Maximilian’s University in Munich and an MBA from Henley. Markus serves on the boards of LigoCyte, Sorbent, Trellis, and Ra

Manfred Horst, Business Development, Merck & Co., France

Dr. Manfred Horst studied medicine in Munich, Montpellier and London and specialised in Allergic Diseases at the University Clinic in Montpellier. After his MBA at INSEAD, Fontainebleau, started a career in the life sciences industry: 7 years with Ciba-Geigy and Novartis, Basel, 2 years in the health insurance business with an affiliate of Munich Re, and now 10 years with Merck & Co./MSD. In his current function as Director Licensing & External Research Europe since 2004.

Mike Johnson, Director, Corporate Partnerships, MRC Technology, UK

Mike JohnsonMike Johnson has a background as Managing Director of two manufacturing companies- Soundcraft Electronics and Combined Optical Industries Limited and latterly with Carclo plc where his remit was to network to bring new technology to the Group which led to the founding of a highly successful start up company - Conductive Inkjet Technology Limited. He holds a First Class Honours Degree in Mechanical Engineering and has studied an MBA. Having worked as a consultant with MRCT for two years, he helped to develop and gain approval for a new 10-Year Strategic Plan. The key change is that as well as working to commercialise the IP for the MRC, MRCT is offering this service to others. In December 2011 he was appointed Director of Corporate Partnerships to build productive partnerships with technology and funding organisations both nationally and internationally. He has a broad commercial perspective across a range of business sectors that help broaden thinking and approach so ensuring delivery of the MRCT strategy.

Patrick Tricoli, Scouting & Partnerting International, Sanofi, France

Patrick TricoliBefore joining the group in 1991 as a project manager in pharmacotoxicology, Patrick Tricoli was a researcher within the CNRS laboratory in 1986 where his main focus area was neuropharmacology and then within the medical research division of Lederle Laboratories (USA), in 1989. In 1996, he joined the company's headquarters in Paris to head up the Promotion of Research and Technology and became, in 2002, Director of Corporate Promotion of Innovation. After 2004, he was Director of Valorization & Innovation for sanofi-aventis. From 2007 to 2009, he was Global Deputy Head of Partnering and Innovation Department. In March 2009, he has been appointed Head of Access to Innovation Europe in 'R&D External Innovation' organization. Patrick is also member of the IMI governance task force and responsible for IMI global office for sanofi-aventis. Patrick Tricoli is a doctor in Pharmaceutical Sciences; has a Masters in Pharmacology and an Executive MBA.

Stuart Henderson, Partner, Head of  European Life Sciences and Healthcare, Deloitte, UK

Stuart HendersonStuart Henderson is a partner and Regional Leader of the Deloitte Life Sciences and Healthcare practice in Europe. Based in Cambridge, he heads a team of some 300 professionals across Europe who are experienced in providing services to the biotechnology and pharmaceutical industries. Stuart has worked for 22 years serving clients in the biotechnology industry providing audit, advisory, corporate finance and due diligence services to a variety of organizations, from start up companies to major academic, biotech, industrial, and pharmaceutical firms. He has acted as reporting accountant on more than 50 public company transactions. A founding member and a former director of the Cambridge Network, Stuart is also an observer on the board of the Eastern Region Biotechnology Initiative and is a former director of the Babraham Institute. In 2003, he served as a member of Sir David Cooksey's Biotechnology Innovation and Growth team reporting to Lord Sainsbury. He currently sits on the BioIndustry Association Finance and Taxation Committee. Stuart is a regular speaker on the global biotechnology conference circuit.

 

 

Recent Blog Posts

May 20, 2013